The Company has also made several recent appointments to its broader leadership team including Dr Mark Uden as Vice President Pharmaceutical Sciences, Dr Oxana Polyakova as Head of Discovery and Craig Taylor as Head of Business Operations. This demonstrates Adaptate’s commitment to establishing an experienced team to drive the development of its portfolio of gamma delta T cell focussed antibodies for therapeutic purposes and advance them into clinical studies.
Adaptate has discovered a number of antibodies that recognise drug targets and have the potential to modulate the activity of gamma delta T cells. Gamma delta T cells are a distinct T cell sub-type that respond to molecular patterns of distress in situ and have been shown to have tremendous potential in treating cancer and other immunological disorders. In 2019, Adaptate spun-out of Gamma Delta Therapeutics, a company developing gamma delta T cell-based therapies, to accelerate antibody-based assets towards clinical studies.
...
